Teva Jumps Most in Two Weeks on FDA Clearance of Cancer Drug

Teva Pharmaceutical Industries Ltd. (TEVA) jumped the most in two weeks after its Pharmachemie BV unit was approved by the U.S. Food & Drug Administration to sell preservative-free methotrexate, a treatment for cancer.

The shares advanced 2.2 percent, the biggest intraday gain since Feb. 15, to 170.40 shekels at 12:39 p.m. in Tel Aviv.

To contact the reporter on this story: Gwen Ackerman in Jerusalem at gackerman@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.